Research ArticleType 2 Diabetes

Genotype-based treatment of type 2 diabetes with an α2A-adrenergic receptor antagonist

See allHide authors and affiliations

Science Translational Medicine  08 Oct 2014:
Vol. 6, Issue 257, pp. 257ra139
DOI: 10.1126/scitranslmed.3009934

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Personalized Diabetes Therapy

The sequencing of the human genome has been heralded as the advent of personalized medicine; however, translating an individual’s genetic variants to tailored therapy for a specific disease is a long road. Now, Tang et al. report that yohimbine, an antagonist for the α2A-adrenergic receptor, can improve insulin secretion in type 2 diabetics who carry a genetic variant in the encoding gene, ADRA2A. Type 2 diabetics with this variant overexpress the α2A-adrenergic receptor and have impaired insulin secretion. In a randomized, placebo-controlled study, yohimbine increased insulin secretion in type 2 diabetics with the risk variant to levels comparable to those without the risk variant. These results suggest that risk variant analysis can lead to individualized therapies that target patient-specific pathophysiology.

View Full Text